Synthetic Virus Designed to Enhance Delivery of New Generation of Pharmaceutical Agents
|
By LabMedica International staff writers Posted on 10 Sep 2014 |

Image: Design of the minimal viral coat protein C-Sn-B (Photo courtesy of Wageningen University).
Dutch scientists have effectively developed an artificial virus that may be used for the delivery of a new generation of pharmaceutical agents, consisting of large biomolecules, by packaging them in a natural manner and delivering them to diseased cells. The artificial virus was developed according to a new theoretic determination of how viruses work, according to the researchers.
The findings were published in the August 31, 2014, issue of the journal Nature Nanotechnology. Specifically, the researchers, from Wageningen University (The Netherlands), along with colleagues from the University of Leiden (The Netherlands), Eindhoven University of Technology (The Netherlands), and Radboud University Nijmegen (The Netherlands) think that the artificial virus technology could be useful for gene therapy.
Standard drugs consist of comparatively small molecules that typically arrive at the desired location without too much difficulty. This is more difficult for newer types of drugs that are being developed; these are comprised of large biomolecules such as proteins and genetic material (i.e., DNA and RNA). For example, to use DNA in gene therapy, the molecule must be delivered to diseased cells in its totality to be effective. However, DNA is inherently incapable of penetrating cells and is rapidly degraded. Therefore natural viruses that have been rendered harmless are used as so-called vectors. These can enter cells efficiently and deliver the therapeutic DNA or RNA molecules.
However, the process of rendering natural viruses harmless still requires improvement. Unwanted side effects have been a hurdle. Therefore, research is also being conducted into alternative virus-like vectors based on synthetic molecules. Regrettably, these have been less effective because it is difficult to precisely duplicate the many behaviors used by viruses. A first important step in mimicking viruses is the effective packaging of individual DNA molecules with a protective coat of smaller molecules. This sounds easier than it is, the researchers reported. Up to now, packing individual DNA molecules with a protective coating of synthetic molecules has not yet been accomplished.
The researchers decided to design and construct artificial viral coat proteins, instead of using synthetic chemistry to coat individual DNA molecules. As part of their study, they used recent theoretic insights into the key aspects of the process of packaging genetic material by natural viral coat proteins. The researchers converted each of these key features into various protein blocks with simple structures. The amino acid sequence of the protein blocks was inspired by natural proteins such as collagen and silk. Artificial viral coat proteins designed in this manner were produced using the natural processes of yeast cells. When the proteins were combined with DNA, they spontaneously formed a highly protective protein coat around each DNA molecule, thus creating artificial viruses. The formation process of the artificial viruses is similar in many ways to that of natural viruses, such as the tobacco mosaic virus, which served as a model for the artificial virus.
This first generation of artificial viruses was found to be as effective as the current methods for delivering DNA to host cells based on synthetic molecules. But the great precision by which DNA molecules are packaged in the artificial virus offers many possibilities to now also build in other virus tricks, the researchers write. In the future, these techniques can hopefully lead to safe and effective approaches for delivering new generations of pharmaceuticals, especially in gene therapy. Moreover, these artificial viruses can also be developed for the many other applications in which viruses are now being used in fields such as biotechnology and nanotechnology.
The artificial viral proteins were designed and produced by scientists of Wageningen UR (University & Research Center). They worked in collaboration with colleagues from Eindhoven University of Technology and Leiden University, who provided contributions based on the theory of spontaneous formation of virus particles, and helped to visualize the resulting artificial virus particles, and partners from Radboud University Nijmegen, who assessed the penetration of the artificial virus particles into living cells.
Related Links:
Wageningen University
University of Leiden
Radboud University Nijmegen
The findings were published in the August 31, 2014, issue of the journal Nature Nanotechnology. Specifically, the researchers, from Wageningen University (The Netherlands), along with colleagues from the University of Leiden (The Netherlands), Eindhoven University of Technology (The Netherlands), and Radboud University Nijmegen (The Netherlands) think that the artificial virus technology could be useful for gene therapy.
Standard drugs consist of comparatively small molecules that typically arrive at the desired location without too much difficulty. This is more difficult for newer types of drugs that are being developed; these are comprised of large biomolecules such as proteins and genetic material (i.e., DNA and RNA). For example, to use DNA in gene therapy, the molecule must be delivered to diseased cells in its totality to be effective. However, DNA is inherently incapable of penetrating cells and is rapidly degraded. Therefore natural viruses that have been rendered harmless are used as so-called vectors. These can enter cells efficiently and deliver the therapeutic DNA or RNA molecules.
However, the process of rendering natural viruses harmless still requires improvement. Unwanted side effects have been a hurdle. Therefore, research is also being conducted into alternative virus-like vectors based on synthetic molecules. Regrettably, these have been less effective because it is difficult to precisely duplicate the many behaviors used by viruses. A first important step in mimicking viruses is the effective packaging of individual DNA molecules with a protective coat of smaller molecules. This sounds easier than it is, the researchers reported. Up to now, packing individual DNA molecules with a protective coating of synthetic molecules has not yet been accomplished.
The researchers decided to design and construct artificial viral coat proteins, instead of using synthetic chemistry to coat individual DNA molecules. As part of their study, they used recent theoretic insights into the key aspects of the process of packaging genetic material by natural viral coat proteins. The researchers converted each of these key features into various protein blocks with simple structures. The amino acid sequence of the protein blocks was inspired by natural proteins such as collagen and silk. Artificial viral coat proteins designed in this manner were produced using the natural processes of yeast cells. When the proteins were combined with DNA, they spontaneously formed a highly protective protein coat around each DNA molecule, thus creating artificial viruses. The formation process of the artificial viruses is similar in many ways to that of natural viruses, such as the tobacco mosaic virus, which served as a model for the artificial virus.
This first generation of artificial viruses was found to be as effective as the current methods for delivering DNA to host cells based on synthetic molecules. But the great precision by which DNA molecules are packaged in the artificial virus offers many possibilities to now also build in other virus tricks, the researchers write. In the future, these techniques can hopefully lead to safe and effective approaches for delivering new generations of pharmaceuticals, especially in gene therapy. Moreover, these artificial viruses can also be developed for the many other applications in which viruses are now being used in fields such as biotechnology and nanotechnology.
The artificial viral proteins were designed and produced by scientists of Wageningen UR (University & Research Center). They worked in collaboration with colleagues from Eindhoven University of Technology and Leiden University, who provided contributions based on the theory of spontaneous formation of virus particles, and helped to visualize the resulting artificial virus particles, and partners from Radboud University Nijmegen, who assessed the penetration of the artificial virus particles into living cells.
Related Links:
Wageningen University
University of Leiden
Radboud University Nijmegen
Latest BioResearch News
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
Adjuvant therapy decisions after curative surgery for colon cancer remain difficult, as conventional clinicopathologic factors often fail to capture residual disease risk. Liquid biopsy approaches that... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








